India's Natco Will File India, Nepal Compulsory License Applications For Generic Versions Of Pfizer's Cancer Drug Celzentry
This article was originally published in PharmAsia News
Executive Summary
NEW DELHI - Natco Pharma told PharmAsia News it plans to file a compulsory license application to sell a generic version of Pfizer's HIV/AIDS drug Celzentry (maraviroc) in Nepal and India, the third such application by the firm, which has cited the high cost of the drugs to the patent office in India as the backbone of its cases